Predictors of Successful First-Line <i>Helicobacter pylori</i> Eradication with Fluoroquinolones in Pakistan: A Prospective Exploration of Demographic and Clinical Factors

• Main Authors: Sumaira Khadim (Author), Iyad Naeem Muhammad (Author), Tanveer Alam (Author), Shahnaz Usman (Author), Hina Rehman (Author), Sajjad Haider (Author)
• Format: Book
• Published: MDPI AG, 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Growing antibiotic resistance complicates <i>H. pylori</i> eradication, posing a public health challenge. Inconclusive research on sociodemographic and clinical factors emphasizes the necessity for further investigations. Hence, this study aims to evaluate the correlation between demographic and clinical factors and the success rates of <i>H. pylori</i> eradication. A group of 162 <i>H. pylori</i>-positive patients were allocated randomly to receive either a ten-day moxifloxacin-based triple therapy or a levofloxacin-based sequential therapy. Eradication success was determined through the stool antigen test. Logistic regression analysis was utilized to figure out potential factors that contribute to <i>H. pylori</i> eradication success. Significantly higher <i>H. pylori</i> eradication rates were observed in the middle age group (COR: 3.671, <i>p</i> = 0.007), among females (<i>p</i> = 0.035), those with BMI ≥ 25 (COR: 2.011, <i>p</i> = 0.045), and non-smokers (COR: 2.718, <i>p</i> = 0.018). In multivariate analysis, age and smoking emerged as significant predictors (<i>p</i> < 0.05). Patients with comorbidities, excluding diabetes and hypertension (COR: 4.432, <i>p</i> = 0.019), dyspepsia (COR: 0.178, <i>p</i> < 0.001), and moxifloxacin triple therapy (COR: 0.194, <i>p</i> = 0.000), exhibited higher chances of eradication (<i>p</i> < 0.05). Further research is vital for tailored approaches to enhance eradication success.

Item Description

10.3390/antibiotics13030211
2079-6382